Outcomes following resection of pancreatic cancer

Journal of Surgical Oncology

Volumn 107, Issue 1, 2013, Pages 97-103

  Witkowski, Elan R ^a   Smith, Jillian K ^a   Tseng, Jennifer F ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

outcomes; pancreatectomy; pancreatic cancer; pancreatic resection

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; SERUM ALBUMIN; TUMOR MARKER;

ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DISEASE SPECIFIC SURVIVAL; HEART INFARCTION; HEPATIC ARTERY; HOSPITALIZATION; HUMAN; LONG TERM SURVIVAL; LUNG EMBOLISM; MEDICARE; MESENTERIC VEIN; METASTASIS; MORBIDITY; MORTALITY; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT CANCER; SCORING SYSTEM; SURGICAL INFECTION; TERMINAL CARE; TREATMENT OUTCOME; UNITED STATES;

CHEMOTHERAPY, ADJUVANT; HUMANS; PANCREATECTOMY; PANCREATIC NEOPLASMS; PATIENT SELECTION; POSTOPERATIVE COMPLICATIONS; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84871268389     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23267     Document Type: Article

References (57)

1. Schnelldorfer T, Adams DB, Warshaw AL, et al.: Forgotten pioneers of pancreatic surgery: Beyond the favorite few. Ann Surg 2008; 247: 191-202.
2. Whipple AO,: Pancreaticoduodenectomy for Islet carcinoma: A five-year follow-up. Ann Surg 1945; 121: 847-852.
3. Rockey EW,: Total pancreatectomy for carcinoma: Case report. Ann Surg 1943; 118: 603-611.
4. Callery MP, Chang KJ, Fishman EK, et al.: Pretreatment assessment of resectable and borderline resectable pancreatic cancer: Expert consensus statement. Ann Surg Oncol 2009; 16: 1727-1733.
5. Gillen S, Schuster T, Friess H, et al. Palliative resections versus palliative bypass procedures in pancreatic cancer-a systematic review. Am J Surg 2012; 203: 496-502.
6. Howlader N, Noone A, Krapcho M, et al.: SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute; 2011.
7. Bilimoria KY, Bentrem DJ, Ko CY, et al.: Validation of the 6th edition AJCC Pancreatic Cancer Staging System: Report from the National Cancer Database. Cancer 2007; 110: 738-744.
8. Bilimoria KY, Bentrem DJ,:, Ko CY, et al.: National failure to operate on early stage pancreatic cancer. Ann Surg 2007; 246: 173-180.
9. Pratt W, Joseph S, Callery MP, et al. POSSUM accurately predicts morbidity for pancreatic resection. Surgery 2008; 143: 8-19.
10. Are C, Afuh C, Ravipati L, et al.: Preoperative nomogram to predict risk of perioperative mortality following pancreatic resections for malignancy. J Gastrointest Surg 2009; 13: 2152-2162.
11. Hill JS, Zhou Z, Simons JP, et al.: A simple risk score to predict in-hospital mortality after pancreatic resection for cancer. Ann Surg Oncol 2010; 17: 1802-1807.
12. Kelly KJ, Greenblatt DY, Wan Y, et al.: Risk stratification for distal pancreatectomy utilizing ACS-NSQIP: Preoperative factors predict morbidity and mortality. J Gastrointest Surg 2011; 15: 250-259; discussion 259-261.
13. Greenblatt DY, Kelly KJ, Rajamanickam V, et al.: Preoperative factors predict perioperative morbidity and mortality after pancreaticoduodenectomy. Ann Surg Oncol 2011; 18: 2126-2135.
14. Venkat R, Puhan MA, Schulick RD, et al.: Predicting the risk of perioperative mortality in patients undergoing pancreaticoduodenectomy: A novel scoring system. Arch Surg 2011; 146: 1277-1284.
15. Vollmer CM Jr, Sanchez N, Gondek S, et al.: A root-cause analysis of mortality following major pancreatectomy. J Gastrointest Surg 2012; 16: 89-102; discussion 102-103.
16. McPhee JT, Hill JS, Whalen GF, et al.: Perioperative mortality for pancreatectomy: A national perspective. Ann Surg 2007; 246: 246-253.
17. Cameron JL, Riall TS, Coleman J, et al. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006; 244: 10-15.
18. Sohn TA, Yeo CJ, Cameron JL, et al.: Resected adenocarcinoma of the pancreas-616 patients: Results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4: 567-579.
19. Trede M, Schwall G, Saeger HD,: Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg 1990; 211: 447-458.
20. Winter JM, Brennan MF, Tang LH, et al.: Survival after resection of pancreatic adenocarcinoma: Results from a single institution over three decades. Ann Surg Oncol 2012; 19: 169-175.
21. Birkmeyer JD, Siewers AE, Finlayson EV, et al.: Hospital volume and surgical mortality in the United States. N Engl J Med 2002; 346: 1128-1137.
22. Balcom JHT, Rattner DW, Warshaw AL, et al.: Ten-year experience with 733 pancreatic resections: Changing indications, older patients, and decreasing length of hospitalization. Arch Surg 2001; 136: 391-398.
23. Hill JS, McPhee JT, Whalen GF, et al.: In-hospital mortality after pancreatic resection for chronic pancreatitis: Population-based estimates from the nationwide inpatient sample. J Am Coll Surg 2009; 209: 468-476.
24. Carroll JE, Smith JK, Simons JP, et al.: Redefining mortality after pancreatic cancer resection. J Gastrointest Surg 2010; 14: 1701-1708.
25. Bassi C, Dervenis C, Butturini G, et al.: Postoperative pancreatic fistula: An international study group (ISGPF) definition. Surgery 2005; 138: 8-13.
26. Simons JP, Shah SA, Ng SC, et al.: National complication rates after pancreatectomy: Beyond mere mortality. J Gastrointest Surg 2009; 13: 1798-1805.
27. Simons JP, Ng SC, McDade TP, et al.: Progress for resectable pancreatic [corrected] cancer?: A population-based assessment of US practices. Cancer 2010; 116: 1681-1690.
28. Kent TS, Sachs TE, Callery MP, et al. Readmission after major pancreatic resection: A necessary evil? J Am Coll Surg 2011; 213: 515-523.
29. Riall TS, Cameron JL, Lillemoe KD, et al.: Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. Surgery 2006; 140: 764-772.
30. Riall TS, Nealon WH, Goodwin JS, et al.: Pancreatic cancer in the general population: Improvements in survival over the last decade. J Gastrointest Surg 2006; 10: 1212-1223; discussion 1223-1214.
31. Birkmeyer JD, Sun Y, Wong SL, et al. Hospital volume and late survival after cancer surgery. Ann Surg 2007; 245: 777-783.
32. O'Connell JB, Maggard MA, Ko CY,: Cancer-directed surgery for localized disease: Decreased use in the elderly. Ann Surg Oncol 2004; 11: 962-969.
33. Baxter NN, Whitson BA, Tuttle TM,: Trends in the treatment and outcome of pancreatic cancer in the United States. Ann Surg Oncol 2007; 14: 1320-1326.
34. Murphy MM, Simons JP, Hill JS, et al.: Pancreatic resection: A key component to reducing racial disparities in pancreatic adenocarcinoma. Cancer 2009; 115: 3979-3990.
35. Murphy MM, Simons JP, Ng SC, et al.: Racial differences in cancer specialist consultation, treatment, and outcomes for locoregional pancreatic adenocarcinoma. Ann Surg Oncol 2009; 16: 2968-2977.
36. Sheffield KM, Boyd CA, Benarroch-Gampel J, et al.: End-of-life care in Medicare beneficiaries dying with pancreatic cancer. Cancer 2011; 117: 5003-5012.
37. Earle CC, Landrum MB, Souza JM, et al.: Aggressiveness of cancer care near the end of life: Is it a quality-of-care issue? J Clin Oncol 2008; 26: 3860-3866.
38. Pezzilli R, Falconi M, Zerbi A, et al.: Clinical and patient-reported outcomes after pancreatoduodenectomy for different diseases: A follow-up study. Pancreas 2011; 40: 938-945.
39. Yeo TP, Burrell SA, Sauter PK, et al.: A progressive postresection walking program significantly improves fatigue and health-related quality of life in pancreas and periampullary cancer patients. J Am Coll Surg 2012; 214: 463-475.
40. National Comprehension Cancer Network: NCCN Practice Guidelines in Oncology: Pancreatic Adenocarcinoma (Version 2.2012). Accessed April 2012. Available at: http://www.nccn.org
41. Conroy T, Desseigne F, Ychou M, et al.: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825.
42. Rhim AD, Mirek ET, Aiello NM, et al.: EMT and dissemination precede pancreatic tumor formation. Cell 2012; 148: 349-361.
43. Haeno H, Gonen M, Davis MB, et al.: Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell 2012; 148: 362-375.
44. Corsini MM, Miller RC, Haddock MG, et al.: Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: The Mayo Clinic experience (1975-2005). J Clin Oncol 2008; 26: 3511-3516.
45. Herman JM, Swartz MJ, Hsu CC, et al.: Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: Results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol 2008; 26: 3503-3510.
46. Merchant NB, Rymer J, Koehler EA, et al.: Adjuvant chemoradiation therapy for pancreatic adenocarcinoma: Who really benefits? J Am Coll Surg 2009; 208: 829-838; discussion 838-841.
47. Piperdi M, McDade TP, Shim JK, et al.: A neoadjuvant strategy for pancreatic adenocarcinoma increases the likelihood of receiving all components of care: Lessons from a single-institution database. HPB 2010; 12: 204-210.
48. Kent TS, Sachs TE, Sanchez N, et al.: Conditional survival in pancreatic cancer: Better than expected. HPB 2011; 13: 876-880.
49. Evans DB, Varadhachary GR, Crane CH, et al.: Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008; 26: 3496-3502.
50. Varadhachary GR, Wolff RA, Crane CH, et al.: Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008; 26: 3487-3495.
51. Kalser MH, Ellenberg SS,: Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985; 120: 899-903.
52. Takada T, Amano H, Yasuda H, et al.: Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002; 95: 1685-1695.
53. Neoptolemos JP, Stocken DD, Friess H, et al.: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-1210.
54. Kosuge T, Kiuchi T, Mukai K, et al. A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. Jpn J Clin Oncol 2006; 36: 159-165.
55. Oettle H, Post S, Neuhaus P, et al.: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 2007; 297: 267-277.
56. Smeenk HG, van Eijck CH, Hop WC, et al.: Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: Long-term results of EORTC trial 40891. Ann Surg 2007; 246: 734-740.
57. Regine WF, Winter KA, Abrams R, et al.: Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol 2011; 18: 1319-1326.